Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.

Tomonori Akasaka,Daisuke Sueta,Yuichiro Arima,Noriaki Tabata,Seiji Takashio,Yasuhiro Izumiya,Eiichiro Yamamoto,Megumi Yamamuro,Kenichi Tsujita,Sunao Kojima,Koichi Kaikita,Ayami Kajiwara,Kazunori Morita,Kentaro Oniki,Junji Saruwatari,Kazuko Nakagawa,Yasuhiro Ogata,Kunihiko Matsui,Seiji Hokimoto

Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.

2016

Tomonori Akasaka
Daisuke Sueta
Yuichiro Arima
Noriaki Tabata
Seiji Takashio
Yasuhiro Izumiya
Eiichiro Yamamoto
Megumi Yamamuro
Kenichi Tsujita
Sunao Kojima
Koichi Kaikita
Ayami Kajiwara
Kazunori Morita
Kentaro Oniki
Junji Saruwatari
Kazuko Nakagawa
Yasuhiro Ogata
Kunihiko Matsui
Seiji Hokimoto

We examined the impact of CYP2C19 genotypes and epoxyeicosatrienoic acid (EET) on patients with microvascular angina (MVA). In results, the CYP2C19 poor metabolizer genotype may be a new candidate risk factor for MVA via EET.

Keywords:

Epoxyeicosatrienoic acid
Risk factor
Microvascular angina
Poor metabolizer
Biochemistry
Diabetes mellitus
CYP2C19
Medicine
C-reactive protein
Case-control study
Hydroxyeicosatetraenoic acid
Arachidonic acid
Genotype

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations